		1
1	UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION	
2		
3		
4	IN RE:	Case No. 1:17-md-2804
5	NATIONAL PRESCRIPTION OPIATE LITIGATION	Cleveland, Ohio Wednesday, July 27, 2022
6		2:00 p.m.
7		
8	TRANSCRIPT OF TELEPHONE CONFERENCE BEFORE THE HONORABLE DAN AARON POLSTER, SENIOR UNITED STATES DISTRICT JUDGE, AND SPECIAL MASTER DAVID COHEN.	
9		
10	AND STECT	
11		
12	For the Plaintiff Tribal Leadership	Steven Skikos, Esq. One Sansome Street, Ste. 2850
13	Committee:	San Francisco, CA 94104 415-546-7300
14		110 010 7000
15	For the Defendant Teva:	Eric W. Sitarchuk, Esq. Morgan Lewis
16		1701 Market Street Philadelphia, PA 19103
17		215-963-5840
18	(Appearances Continued to page 2.)	
19		
20		
21	Official Court Reporter:	Heidi Blueskye Geizer, RMR, CRR 7-189 U.S. Court House
22		801 West Superior Avenue Cleveland, Ohio 44113
23		216-357-7092 Heidi Geizer@ohnd.uscourts.gov
24		_
25	Proceedings recorded by mechanical stenography; transcript produced by computer-aided transcription.	

1 APPEARANCES: (Continued.) 2 For the Plaintiff Lloyd B. Miller, Esq. Tribal Leadership Don Simon, Esq. 3 Committee: Tara D. Sutton, Esq. Jan Joseph, Esq. 4 Roe Frazier, Esq. Elizabeth J. Cabraser, Esq. Eric B. Fastiff, Esq. 5 Timothy Q. Purdon, Esq. 6 Mark Crawford, Esq. Geoffrey Strommer, Esq. 7 Caroline P. Mayhew, Esq. Peter Mougey, Esq. 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

1 AFTERNOON SESSION, WEDNESDAY, JULY 27, 2022 2:00 P.M. 2 SPECIAL MASTER: I'll just do a brief 3 introduction. Our court reporter's name today is Heidi, and because 4 5 of course we're not appearing live, if everybody who speaks 6 would mention who they are, that would be helpful. 7 We're here in the Opioid MDL, that's MDL 2804, and the 8 reason we're here today is for the Tribal Leadership 9 Committee, which is being represented by Steve Skikos, to 10 discuss the settlement that the tribes have reached with 11 Teva, which is represented today by Eric Sitarchuk; so I 12 think that Eric and Steve will be the ones primarily who are 13 presenting. And there are also on the phone quite a number 14 of other attorneys representing tribes. 15 And so, Judge, the parties are going to explain to you 16 the settlement agreement that they've reached, and I'll hand 17 it off to Steve. 18 MR. SKIKOS: Thank you. I just want to make surer Eric Sitarchuk is on. 19 20 MR. SITARCHUK: I am. 21 Good afternoon, Your Honor, and everyone else. 22 MR. SKIKOS: Okay. We have an agreed 23 statement. 24 On behalf of the MDL Tribal Leadership Committee, we 25 would like to thank Your Honor, Special Master David Cohen,

and counsel for Teva, for the opportunity to present the financial terms of this settlement in principle.

A few points of background. In this case, over 170 tribal nations filed suit in the MDL and in this Court appointed by the Tribal Leadership Committee to serve the interests of all tribes.

In October of 2018, in response to a motion to dismiss and in light of the experience in Tobacco in which the tribes were excluded, over 450 tribes and tribal organizations signed on to the tribal amicus briefs. This filing represents 70 percent of all federally-recognized tribes and an estimated 85 percent of all tribal citizens. This was a clear and unified statement in support of the tribal litigation efforts in the Opioid MDL and in support of tribal rights to resolve their own cases.

The TLC itself is a combination of firms that historically represent tribes, firms that work on and with the PEC, and firms responsible for the efforts on liability discovery, experts, law and motion, and trial.

And as you know, Your Honor, the tribes have one of the bellwether cases in Cherokee Nation and further helped commence the case against the generic manufacturers when Blackfeet and Muscogee Creek won a series of rulings in June of 2019. The tribes are additive and necessary cases to the two cases of this magnitude, and this led to a settlement in

principle.

The financial terms with Teva is that Teva will pay \$119 million over 13 years plus product. The settlement in principle is conditioned first on an agreement with Allergan on indemnification and on an agreement with Allergan on their participation in the global.

Now a few points on eligibility and effective date.

The aggregate settlement will be presented to all federally-recognized tribes. Both litigating and non-litigating tribes will have the right to participate in the settlement. The tribe does not have to file suit to participate.

There are litigating tribal healthcare organizations that are also eligible to participate. On the subject of tribal healthcare, 85 percent of the total settlement funds in the Teva deal will be spent on drug treatment and related abatement programs.

Dean Kevin Washburn, former Indian Health Service

Director Mary Smith, and expert Kathy Hannan, all tribal

citizens, will share the responsibility for the

implementation of the settlement under the supervision of

court-appointed administrator David Cohen. They will also

lead the outreach and notice to non-litigating tribes.

Each participating tribal entity will have the sole, ultimate, and final say over which abatement uses are best

for that tribal entity as that tribal entity continues to address the opioid crisis. David Cohen and Wayne Phillips will jointly determine the final intertribal allocation. Each tribal entity shall have the right to meaningfully participate in the final allocation process and a right to be heard prior to the final allocation order specific to this opioid crisis.

Tribal participation will be important. On that note, the current participation rate, thanks to the TLC, for the Johnson & Johnson settlement is over 98 percent with zero affirmative opt-outs, and we have reached effective date with Johnson & Johnson. It is the goal of the TLC to reach and to mirror the participation results here.

The TLC which is represented on this call believes in the overall value, purpose, and reliability of the settlement procedures and is committed to work in cooperation with you, Your Honor, Special Master Cohen, Judge Wayne Phillips, the directors, and the company, to reach participation requirements once we finish the MSA with Teva.

Referring to the terms of the terms sheet -- I don't have it yet. Anyway, last point. Finally, the aggregate amount of all opioid-related settlements with the tribes is almost exactly one billion dollars. And I want to thank Your Honor for that.

In coordination with the PEC, the TLC continues to pursue the cases against the pharmacies and the remaining manufacturers, including the generics, and to protect the tribal claims in the Perdue and Mallinckrodt bankruptcies.

That's all I have to say. Eric, it's up to you.

MR. SITARCHUK: Thank you, Steven.

And Your Honor, I would just like to thank the Court and the Court's staff, obviously, and Special Master Cohen, for all the support that you've provided throughout these negotiations. It's been indispensable. And I'd also like to thank Steve Skikos for the tireless work that he put into bringing this agreement in principle across the finish line.

THE COURT: All right. Well, I appreciate all the hard efforts and obviously the results, and I'm committed to making sure that it gets concluded. If you run into snags you should contact me or Special Master Cohen, and I'll help you work through them. It's obviously very significant to all the tribal nations and to Teva.

So again, I appreciate everyone's hard work.

MR. SKIKOS: Thank you, Your Honor. And David, we're sending you all the names of the TLC participants for the record.

SPECIAL MASTER: Thank you all very much. Have a good afternoon.

25 - - - -